The first findings from a prospective, multicenter, open-label, phase 1b/2a clinical trial anti-BCMA rCAR T-cells (NCT04146051) (61) exhibited promising therapeutic outcomes in adult patients with generalized MG. This evidence concerns the gene TNFRSF17 and myasthenia gravis.